However, clinical responses in mRCC were previously demonstrated by others in vaccine-based clinical trials (without IFN-α) with cultured CD83 + blood DC loaded with autologous tumor cell lysates [50], DC pulsed with MUC1-derived peptides [51], a multipeptide cancer vaccine [52] and RNA coding for tumor-associated antigens [53]. The gene discussed is MUC1; the disease is neoplasm.